Queensland University of Technology

banner

Queensland University of Technology is a large multidisciplinary research university. QUT's Institute of Health and Biomedical Innovation is a collaborative institute that is focused on three broad health areas  prevention, mind and body health, and recovery.
 
As part of this node, researchers within QUT aim to:

  • Identify genes involved in common, complex human disorders;
  • Define the molecular basis of gene dysfunction and how this relates to disease;
  • Translate this information into new diagnostic tools; and
  • Develop specific and individualised treatments targeted toward the genetic causes of chronic disease.  

Accreditations

HGSA, NATA  

Year of Establishment

2008 

Access and Pricing

Please email or call us to discuss new projects and pricing.

Previous Clients

The IHBI is currently undertaking the following translational research studies:
  • Cancer research - research studies aimed at identifying genes involved in cancer development and new anti-cancer treatments for breast cancer, lymphoma and melanoma.  These studies include the identification of 2 new genes associated with treatment response in lymphoma.  
  • Migraine research – the identification of migraine gene mutations and corresponding treatments.  Based on the positive findings of two previous clinical studies a Phase III clinical trial is currently underway with TIA Queensland node partner CIPDD, and industry partner Blackmores investigating the dosage efficacy of a nutraceutical treatment for migraine with aura sufferers.   
  • Envirogenomic profiling  - a new methodology has been developed to identify a genetic risk signature and treatment response which is being investigated for applications in Crohn’s Disease, hypertension and migraine.   
  • Diagnostic services – The NATA accredited diagnostic service available at the IHBI has been critical to the identification of novel rare variants and mutations that cause migraine or stroke related disease. This includes 2 novel polymorphisms identified through FHM1 testing and 3 novel variants identified in the NOTCH3 gene from CADASIL testing.  
  • The Queensland Breast Cancer Biobank - a collaboration of Griffith University and Cancer Council Queensland (CCQ), is a collection of DNA and RNA obtained from ~3,000 breast cancer patients supported by detailed clinical and demographic data (to be completed by 2014). The Biobank provides a critical foundation for extensive studies into genetic susceptibility, gene expression variation and envirogenomic profiling in relation to disease development, prognosis and treatment response.   
  • Cardiovascular disease - Data mining of an extensive Norfolk Island epidemiological dataset is underway to identify new molecular markers related to cardiovascular risk factors and bone density to aid in the development of genetic signatures and molecular diagnostics.

 Contact information

Contact: Christine Lane
Email: christine.lane@qut.edu.au
Phone: +61 (0)7 3138 6083

KEY TECHNOLOGY

SERVICES

Life Technologies PGM Sequencer (Ion Torrent)

Genetic testing including diagnosis of severe migraine and stroke related conditions

Sequenom MassArray Analyzer 4.0 (including associated server & software)

Gene mapping & the characterisation of gene dysfunction

 Corbett QSeq DNA sequencer

Examination of identified variants in our extensive population repositories for target validation

Tissue culture facility

Clinical Trials

  • Study design and development
  • Recruitment and training
  • Ethics submissions
  • Trial implementation
  • Data management and validation
  • Statistical randomization analysis and reporting 

Bioinformatics analysis computers & accessories

Molecular biological analysis equipment including tissue bank and storage capabilities